Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Aug;9(8):2235-2237.
doi: 10.21037/jtd.2017.06.133.

Role of consolidative stereotactic ablative radiotherapy in patients with oligometastatic non-small cell lung cancer

Umberto Ricardi  1 , Niccolò Giaj Levra  2 , Serena Badellino  1 , Filippo Alongi  2   3
Affiliations
Editorial

Role of consolidative stereotactic ablative radiotherapy in patients with oligometastatic non-small cell lung cancer

Umberto Ricardi et al. J Thorac Dis. 2017 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on

References

    1. Villaruz LC, Kubicek GJ, Socinski MA. Management of non-small cell lung cancer with oligometastasis. Curr Oncol Rep 2012;14:333-41. 10.1007/s11912-012-0240-1 - DOI - PMC - PubMed
    1. Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 2010;40:107-11. 10.1093/jjco/hyp167 - DOI - PMC - PubMed
    1. Shultz DB, Filippi AR, Thariat J, et al. Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer. J Thorac Oncol 2014;9:1426-33. 10.1097/JTO.0000000000000317 - DOI - PubMed
    1. Alongi F, Arcangeli S, Filippi AR, et al. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 2012;17:1100-7. 10.1634/theoncologist.2012-0092 - DOI - PMC - PubMed
    1. Gomez DR, Blumenschein GR, Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 2016;17:1672-82. 10.1016/S1470-2045(16)30532-0 - DOI - PMC - PubMed

LinkOut - more resources